Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study

被引：0
|
作者：
Gardner, Thomas A.
Petrylak, Daniel Peter
Corman, John M.
Hall, Simon
Weinstein, Ralph
Keyser, Robert
Sims, Robert Brownell
Sanders, Amanda
Sheikh, Nadeem A.
Higano, Celestia S.
机构：
[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Columbia Univ, Med Ctr, New York, NY USA
[3] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] US Oncol, Portland, OR USA
[6] Dendreon Corp, Seattle, WA USA
[7] Univ Washington, Sch Med, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
148
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Building on Sipuleucel-T for Immunologic Treatment of Castration-Resistant Prostate Cancer
    Shore, Neal D.
    Mantz, Constantine A.
    Dosoretz, Daniel E.
    Fernandez, Eduardo
    Myslicki, Francisco A.
    McCoy, Candice
    Finkelstein, Steven Eric
    Fishman, Mayer N.
    CANCER CONTROL, 2013, 20 (01) : 7 - 16
  • [32] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Editorial Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2011, 185 (03): : 897 - 898
  • [33] First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC).
    De Santis, Maria
    Mulders, Peter
    Fizazi, Karim
    Gray, Todd E.
    McCoy, Candice
    Stubbs, Andrew
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial
    Small, Eric Jay
    Higano, Celestia S.
    Kantoff, Philip W.
    Whitmore, James Boyd
    Frohlich, Mark Walter
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED
    Sartor, A. Oliver
    Cooperberg, Matthew R.
    Vogelzang, Nicholas J.
    Scholz, Mark Creamer
    Concepcion, Raoul S.
    Berry, William R.
    Pieczonka, Christopher
    Dakhil, Shaker R.
    Vacirca, Jeffrey L.
    Sandler, Andrew
    McCoy, Candice
    Whitmore, James Boyd
    Tyler, Robert Claude
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.
    Wei, Xiao X.
    Hamid, Anis
    He, Monica
    Harshman, Lauren Christine
    Choueiri, Toni K.
    Sonpavde, Guru
    Pomerantz, Mark
    Taplin, Mary-Ellen
    Sweeney, Christopher
    Choudhury, Atish Dipankar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).
    Hepgur, Mehmet Faith
    Dorff, Tanya B.
    Cai, Jie
    Reed, Mary
    Chan, Betty
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Clinical and biologic factors for immune response to sipuleucel-T (SipT) for metastatic castrate-resistant prostate cancer (mCRPC)
    Hepgur, Mehmet Faith
    Dorff, Tanya B.
    Brining, Lucy
    Cai, Jie
    Pinski, Jacek K.
    Reed, Mary
    Luther, Michael
    Chan, Betty
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] Phase II cohort study in patients with metastatic castration-resistant prostate cancer (mCRPC) with new cohorts
    Rexer, Heidrun
    Retz, Margitta
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (06) : 504 - 505
  • [40] Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer
    Gong, Cynthia L.
    Hay, Joel W.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (10): : 1417 - 1425
12345